



ASX Announcement

14 April 2020

Creso Pharma signs binding letter of intent to establish a strategic collaboration for its innovative hemp derived therapeutic products in Pakistan and additional new markets

Highlights

- Creso Pharma has entered a binding letter of intent with Highnoon Laboratories (PSX: HINOON) and Route2 Health to enter a strategic collaboration to explore expanding the distribution of Creso Pharma's products into Pakistan
- Pakistan has a population of over 200 million and a wide range of unmet needs that can be addressed by a targeted portfolio of products
- The parties have agreed to explore broadening the strategic collaboration to include several additional overseas markets

Creso Pharma Limited (ASX:CPH, FRA:1X8, 'Creso Pharma' or 'the Company') is pleased to announce a collaboration with Highnoon Laboratories Limited (PSX: HINOON) (**'Highnoon'**), one of Pakistan's most successful and progressive pharmaceutical companies, and Route2 Health Limited (**'Route2'**), a leading player in the nutritional supplements area. Both Highnoon and Route2 are entities incorporated in Pakistan.

Creso Pharma has entered a binding letter of intent with Highnoon and Route2 whereby the parties will look to enter into a strategic collaboration to expand distribution of its innovative hemp derived therapeutic products into Pakistan.

Subject to further regulatory approvals, the parties have also agreed to consider leveraging their international reach to explore broadening the strategic collaboration to include the additional markets of Afghanistan, Azerbaijan, Bangladesh, Cambodia, Georgia, the Maldives, Myanmar, the Philippines, Tajikistan, Turkmenistan, Uzbekistan, and Vietnam.

Under the letter of intent the parties have agreed to formalise the terms of their strategic collaboration in a definitive agreement to be executed within the next three months. Any material distribution of Creso Pharma's products into Pakistan will be subject to the entry into the definitive agreement.



Pakistan has a population of over 200 million and a wide range of unmet needs that can be addressed by a targeted portfolio of products.

Creso Pharma's portfolio of cannabis and hemp-derived products focuses on four key areas: therapeutics, nutraceuticals, animal health, and cosmetics. The Company currently has a portfolio of 13 products, eight of which have been commercialised and are generating revenues, with the remaining pending commercialisation.

Dr. Miri Halperin Wernli, Creso Pharma's CEO and co-founder said: "Our mission is to deliver access to affordable, high quality, broad spectrum, GMP products for the betterment of people's lives everywhere. We are delighted to announce this partnership with Highnoon Laboratories and Route 2 Health, leading players in Pakistan's pharmaceutical and nutritional supplement sectors. Through this partnership, we hope to provide the opportunity for millions of people to have access to our innovative products."

Tausif Khan, the Chairman of Highnoon Laboratories and Route 2 Health said: "We are delighted to partner with leading global cannabis company Creso Pharma on this endeavour. There exists a vast amount of real-world and strong clinical evidence which supports the safety and efficacy of hemp-based therapeutic products. However, due to the current regulations and lack of education about cannabis in Pakistan, there remain considerable obstacles to patient access. We are working closely with the relevant authorities in Pakistan to pave a way for patients and consumers to gain access to the benefits of hemp-derived products."

Ends

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000



About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.

It develops cannabis and hemp derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About Highnoon Laboratories Ltd. (PSX: HINOON)

www.highnoon-labs.com/

Highnoon Laboratories Limited was incorporated as a private limited company in Pakistan in 1984, converted into a public limited company in 1985 and its shares are quoted on Pakistan Stock Exchange since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products. The registered office of the Company is situated at 17.5 Km, Multan Road, Lahore.

About Route 2 Health

www.route2health.net

Route 2 Health is located in Lahore, Pakistan. Its manufacturing facility is approved by the Drug Regulatory Authority of Pakistan to manufacture herbal and nutritional products and is both GMP and ISO certified. Route 2 Health also has a number of notable national and international partnerships, including with Highnoon Laboratories, Himalaya and Engelhard Arzneimittel.



Forward Looking statements

This announcement contains forward-looking statements with respect to Creso Pharma and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso Pharma could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso Pharma and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso Pharma has no obligation to up-date such statements, except to the extent required by applicable laws.